NICE confirms members of new QOF Indicator Advisory C'tee

8 June 2009

The UK's National Institute for Health and Clinical Excellence (NICE) has announced the establishment of the new independent Primary Care  Quality and Outcomes Framework (QOF) Indicator Advisory Committee.

The Advisory Committee is made up of 29 members with a range of  expertise from across primary care and includes three regional directors  of public health, nine general practitioners, seven GP academics, three  lay representatives and seven other health care professionals from a  range of disciplines; one position on the committee remains vacant to  be filled at a later date. The committee, whose membership is drawn from  the four UK nations, is responsible for reviewing existing QOF  indicators and recommending new ones before producing a national "menu"  of approved indicators which will be made available through the NICE web  site.

The Advisory Committee's first meeting was chaired by Colin Hunter who  will work closely with the NICE QOF team and the consortium (consisting  of the National Primary Care Research and Development Centre/York  Health Economics Consortium (YHEC)/Royal College of General  Practitioners (RCGP)) commissioned by the NICE to develop and review  indicators on clinical or public health topics recommended by the  Advisory Committee.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK







Today's issue

Company Spotlight